KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Assets (2016 - 2025)

Pacira BioSciences has reported Current Assets over the past 16 years, most recently at $548.0 million for Q4 2025.

  • Quarterly results put Current Assets at $548.0 million for Q4 2025, down 26.46% from a year ago — trailing twelve months through Dec 2025 was $548.0 million (down 26.46% YoY), and the annual figure for FY2025 was $548.0 million, down 26.46%.
  • Current Assets for Q4 2025 was $548.0 million at Pacira BioSciences, down from $562.8 million in the prior quarter.
  • Over the last five years, Current Assets for PCRX hit a ceiling of $866.0 million in Q4 2021 and a floor of $376.1 million in Q1 2023.
  • Median Current Assets over the past 5 years was $597.5 million (2024), compared with a mean of $620.8 million.
  • Biggest five-year swings in Current Assets: skyrocketed 73.88% in 2021 and later plummeted 43.61% in 2023.
  • Pacira BioSciences' Current Assets stood at $866.0 million in 2021, then plummeted by 42.46% to $498.3 million in 2022, then grew by 2.34% to $510.0 million in 2023, then skyrocketed by 46.11% to $745.1 million in 2024, then decreased by 26.46% to $548.0 million in 2025.
  • The last three reported values for Current Assets were $548.0 million (Q4 2025), $562.8 million (Q3 2025), and $745.6 million (Q2 2025) per Business Quant data.